Two Russian-made coronavirus treatment drugs have been cleared for pharmacy sale, allowing for widespread at-home treatment of the infection, the Health Ministry announced in a statement to the state-run RIA-Novosti news agency Thursday.
Both drugs are Russia-manufactured variants of favipiravir, the generic version of an anti-flu medication developed by Japan’s Fujifilm. Clinical trials of the pill-form drug showed reduced recovery times among coronavirus patients, though only Russia, India and China officially recommend it for treating the virus.
One of the approved medications, registered under brand name Areplivir, will appear on pharmacy shelves in most Russian regions starting Monday, the head of its manufacturer Promomed confirmed to the Kommersant business daily.
Another drug, Koronavir, is expected to become available at the same time.
According to Koronavir manufacturer R-Farm, the drug minimizes complications associated with Covid-19. Over 50% of clinical study patients showed improvements after seven days of treatment, which is 1.5 times better than the control group which didn’t take the drug, the manufacturer told the RBC news website.
The Health Ministry has previously approved one other brand of favipiravir, Avifavir, though its manufacture has largely been export-oriented with supplies reaching neighboring Belarus and Kazakhstan.
Despite early hopes voiced by then-Prime Minister Shinzo Abe, favipiravir has not been approved for Covid-19 treatment in Japan after Fujifilm’s own trials yielded “inconclusive” results.
Allowing patients with less-severe coronavirus cases to undergo outpatient treatment is expected to reduce pressure on Russia’s healthcare sector and keep hospital beds open for patients with severe bouts of the virus.
While Russia has placed high stakes in its Sputnik V coronavirus vaccine, currently in the final trial stage, nearly half of the country remains skeptical toward it, saying they would “never” vaccinate.
Russia has confirmed more than 1 million infections and more than 19,000 deaths from coronavirus so far.
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
